Clinical Trial Update: A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating two HIV-1 vaccine regimens (DNA-MVA-Env Protein and DNA-Env Protein) with PrEP has completed in Africa.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• DNA-Env Protein HIV-1 Vaccine Regimen (DNA-Env HIV-1 vaccine regimen)
• DNA-MVA-Env Protein HIV-1 Vaccine Regimen (DNA-MVA-Env HIV-1 vaccine regimen)

Snippet

Sponsor: MRC/UVRI and LSHTM Uganda Research Unit | Conditions: HIV Infections | Phase 2 | Status: COMPLETED